JP2016535094A5 - - Google Patents

Info

Publication number

JP2016535094A5

JP2016535094A5 JP2016551030A JP2016551030A JP2016535094A5 JP 2016535094 A5 JP2016535094 A5 JP 2016535094A5 JP 2016551030 A JP2016551030 A JP 2016551030A JP 2016551030 A JP2016551030 A JP 2016551030A JP 2016535094 A5 JP2016535094 A5 JP 2016535094A5

Authority

JP

Japan

Prior art keywords

composition

acid

microparticles

polyinosinic

polycytidylic

Prior art date

2014-11-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 57
• 239000002253 acid Substances 0.000 claims description 34
• 239000011859 microparticle Substances 0.000 claims description 26
• 229920000642 polymer Polymers 0.000 claims description 18
• 229920002472 Starch Polymers 0.000 claims description 14
• 235000019698 starch Nutrition 0.000 claims description 14
• 239000008107 starch Substances 0.000 claims description 14
• 229920001592 potato starch Polymers 0.000 claims description 8
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
• 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
• 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
• WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
• 239000003814 drug Substances 0.000 claims description 6
• 229940014041 hyaluronate Drugs 0.000 claims description 6
• 229940116317 potato starch Drugs 0.000 claims description 6
• 238000000034 method Methods 0.000 claims description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
• 239000007788 liquid Substances 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 4
• 239000003960 organic solvent Substances 0.000 claims description 4
• 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
• 239000000843 powder Substances 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• 238000001694 spray drying Methods 0.000 claims description 3
• 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
• 239000002245 particle Substances 0.000 claims description 2
• 229940032147 starch Drugs 0.000 claims 10
• 239000010419 fine particle Substances 0.000 claims 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
• 230000009385 viral infection Effects 0.000 claims 7
• 208000036142 Viral infection Diseases 0.000 claims 5
• 241000430519 Human rhinovirus sp. Species 0.000 claims 2
• 206010061494 Rhinovirus infection Diseases 0.000 claims 2
• 208000020029 respiratory tract infectious disease Diseases 0.000 claims 2
• 241000712461 unidentified influenza virus Species 0.000 claims 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• -1 di Yagaimodenpun Substances 0.000 claims 1
• 210000002345 respiratory system Anatomy 0.000 claims 1
• 150000003839 salts Chemical class 0.000 claims 1
• 159000000000 sodium salts Chemical class 0.000 claims 1
• 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960001375 lactose Drugs 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1